stockrowSpyre Therapeutics, Inc.
SYRE Healthcare Biotechnology
Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.
- EPS
- −624.8%
- Free cash flow
- −108.8%
Quarter to September 2026, against a year earlier
Follow SYRE
Alert me
Spyre Therapeutics, Inc. (SYRE) EV/FCF
As of 5 November 2026, Spyre Therapeutics, Inc. (SYRE) trades at a EV/FCF of −30.3×. Over the past ten years it has ranged from −38.8× (August 2026) to 2.9× (July 2023); the current reading is higher than 3% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2023 | 0.0× | (86.93%) |
| FY2022 | 0.3× | — |
| FY2021 | −4.0× | — |
| FY2018 | −2.5× | — |
| FY2017 | −1.2× | — |
| FY2016 | 1.0× | (45.31%) |
| FY2015 | 1.8× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Dec 2023 | 0.0× | (98.85%) |
| Jun 2023 | 2.9× | 1,743.22% |
| Mar 2023 | 0.2× | (38.14%) |
| Dec 2022 | 0.3× | (15.17%) |
| 19 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| TWST Twist Bioscience Corporation compare | −77.9× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −64.5× |
| IBRX ImmunityBio, Inc. compare | −32.5× |
| SYRE Spyre Therapeutics, Inc. | −30.3× |
| CYTK Cytokinetics, Incorporated compare | −12.7× |
| KRYS Krystal Biotech, Inc. compare | 25.7× |
| PTGX Protagonist Therapeutics, Inc. compare | 62.4× |
| CAI Caris Life Sciences,�Inc. compare | 181× |
| TGTX TG Therapeutics, Inc. compare | 485× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on SYRE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement